Long-term clinical remission maintained after cessation of zidovudine and interferon-α therapy in chronic adult T-cell leukemia/lymphoma

[1]  Charles R. M. Bangham,et al.  CADM1/TSLC1 Identifies HTLV-1-Infected Cells and Determines Their Susceptibility to CTL-Mediated Lysis , 2016, PLoS pathogens.

[2]  T. Taki,et al.  Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan , 2016, Pediatric blood & cancer.

[3]  S. Hanada,et al.  Treatment and survival among 1594 patients with ATL. , 2015, Blood.

[4]  R. Ueda,et al.  Dose‐intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma: a randomized phase II study , 2015, British journal of haematology.

[5]  B. Bain,et al.  Pre-morbid human T-lymphotropic virus type I proviral load, rather than percentage of abnormal lymphocytes, is associated with an increased risk of aggressive adult T-cell leukemia/lymphoma , 2013, Haematologica.

[6]  G. Taylor,et al.  Human T cell lymphotropic virus type 1 viral load variability and long-term trends in asymptomatic carriers and in patients with human T cell lymphotropic virus type 1-related diseases. , 2012, AIDS research and human retroviruses.

[7]  C. Bangham,et al.  HTLV-1-infected T cells contain a single integrated provirus in natural infection. , 2012, Blood.

[8]  A. Gessain,et al.  Epidemiological Aspects and World Distribution of HTLV-1 Infection , 2012, Front. Microbio..

[9]  F. Bushman,et al.  The host genomic environment of the provirus determines the abundance of HTLV-1–infected T-cell clones , 2011, Blood.

[10]  A. Bazarbachi,et al.  Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. Matsuo,et al.  Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. , 2010, Blood.

[12]  K. Yamaguchi,et al.  Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. , 2010, Blood.

[13]  M. Tomonaga,et al.  Long-term study of indolent adult T-cell leukemia-lymphoma. , 2007, Blood.

[14]  R. Ueda,et al.  VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  K. Yamaguchi,et al.  Human T lymphotropic virus type-I and adult T-cell leukemia in Japan , 2002, International journal of hematology.

[16]  M. Tomonaga,et al.  Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. , 1997, Blood.

[17]  M. Matsuoka,et al.  Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. , 1996, Blood.

[18]  M. Kaplan,et al.  Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. , 1995, The New England journal of medicine.

[19]  E. Macintyre,et al.  Treatment of Adult T-Cell Leukemia-Lymphoma with Zidovudine and Interferon Alfa , 1995 .

[20]  H. Taguchi.  [Treatment of adult T-cell leukemia]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[21]  M. Shimoyama,et al.  Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphoma , 1991, British journal of haematology.